TP53 and hemoglobin measurement: We assess the effects of the established MDM4 inhibitor NSC207895 (XI-006), which is known to inhibit gene expression of MDM4 by physically binding its promoter and preventing transcription, induce apoptosis, and activate the p53 signaling pathway23, and the peptide dual MDM2 and MDM4 inhibitor ATSP-7041 in a range of in vitro and in vivo assays to show that targeting MDM4 in HB may be an effective treatment strategy for this disease.